Medically reviewed by Drugs.com. Last updated on Jan 16, 2019.
(moe MET a sone)
- Mometasone Furoate
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Aerosol, Inhalation, as furoate:
Asmanex HFA: 100 mcg/actuation (13 g); 200 mcg/actuation (13 g)
Aerosol Powder Breath Activated, Inhalation, as furoate:
Asmanex 120 Metered Doses: 220 mcg/INH (1 ea) [contains milk protein]
Asmanex 14 Metered Doses: 220 mcg/INH (1 ea) [contains milk protein]
Asmanex 30 Metered Doses: 110 mcg/INH (1 ea); 220 mcg/INH (1 ea) [contains milk protein]
Asmanex 60 Metered Doses: 220 mcg/INH (1 ea) [contains milk protein]
Asmanex 7 Metered Doses: 110 mcg/INH (1 ea) [contains milk protein]
Brand Names: U.S.
- Asmanex 120 Metered Doses
- Asmanex 14 Metered Doses
- Asmanex 30 Metered Doses
- Asmanex 60 Metered Doses
- Asmanex 7 Metered Doses
- Asmanex HFA
- Corticosteroid, Inhalant (Oral)
May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins). Leukocytes and macrophages may have to be present for the initiation of responses mediated by the above substances. Inhibits the margination and subsequent cell migration to the area of injury, and also reverses the dilatation and increased vessel permeability in the area resulting in decreased access of cells to the sites of injury.
<1%; clinical effects are due to direct local effect, rather than systemic absorption
Vd: 152 L
Extensive in the liver to multiple metabolites; no major metabolites are detectable in the plasma; in vitro incubation studies identified one minor metabolite, 6 Beta-hydroxymometasone furoate, formed via cytochrome P450 CYP3A4 pathway
Feces (~74%), urine (~8%)
Onset of Action
Maximum effects may not be evident for ≥1 to 2 weeks
Time to Peak
Plasma: 0.5 to 2.5 hours
Duration of Action
Duration after discontinuation: Several days or more
Mean: 5 hours
98% to 99%
Use: Labeled Indications
Asthma: Maintenance treatment of asthma as prophylactic therapy in patients ≥4 years of age (Asmanex Twisthaler) and ≥12 years of age (Asmanex HFA).
Limitations of use: Not indicated for the relief of acute bronchospasm.
Guideline recommendations: A low-dose inhaled corticosteroid (in addition to an as-needed short-acting beta-2 agonist) is the initial preferred long-term control medication for children, adolescents, and adult patients with persistent asthma who are candidates for treatment according to a step-wise treatment approach (GINA 2018; NAEPP 2007).
Hypersensitivity to mometasone or any component of the formulation; hypersensitivity to milk proteins (Asmanex Twisthaler only); primary treatment of status asthmaticus or other acute episodes of asthma for which intensive measures are required
Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.
Canadian labeling: Additional contraindications (not in US labeling): Untreated systemic fungal, bacterial, viral, or parasitic infections; active or quiet tuberculosis infection of the respiratory tract; ocular herpes simplex
Note: The recommended starting dose is based on previous asthma therapy and disease severity; may increase dose after 2 weeks of therapy in patients who are not adequately controlled. Titrate to the lowest effective dose once asthma is controlled.
Asthma: Oral inhalation: Note: To decrease the severity or duration of an asthma exacerbation, may consider temporarily quadrupling the dose (early in the course of illness) in patients with mild to moderate asthma with a mild flare in symptoms. Reserve this approach for patients with no prior history of life-threatening asthma exacerbations, and in those with good self-management skills; return to baseline dose after normalization of symptoms or at a maximum of 14 days of the quadrupled dose (Fanta 2019; GINA 2018; McKeever 2018).
Patients who previously received bronchodilators alone: Asmanex Twisthaler: Dry-powder inhaler: Initial: 220 mcg once daily in the evening (maximum: 440 mcg/day [administered once daily in the evening or in divided doses twice daily])
Patients who previously received inhaled corticosteroids:
Asmanex HFA: Metered-dose inhaler: Maximum: 400 mcg twice daily (800 mcg/day)
Inhaled medium-dose corticosteroids: Asmanex HFA 100 mcg inhaler: 200 mcg twice daily
Inhaled high-dose corticosteroids: Asmanex HFA 200 mcg inhaler: 400 mcg twice daily
Asmanex Twisthaler: Dry-powder inhaler: Initial: 220 mcg once daily in the evening (maximum: 440 mcg/day [administered once daily in the evening or in divided doses twice daily])
Patients who previously received oral corticosteroids: Note: Prednisone should be reduced slowly (ie, no faster than 2.5 mg daily on a weekly basis), beginning after at least 1 week of mometasone use.
Asmanex HFA: Metered-dose inhaler: Initial: 400 mcg twice daily (maximum: 800 mcg/day)
Asmanex Twisthaler: Dry-powder inhaler: Initial: 440 mcg twice daily (maximum: 880 mcg/day)
Global Initiative for Asthma guidelines (GINA 2018): Dry powder inhaler:
Low-dose therapy: 110 to 220 mcg/day
Medium-dose therapy: >220 to 440 mcg/day
High-dose therapy: >440 mcg/day
National Asthma Education and Prevention Program guidelines (NAEPP 2007): Dry powder inhaler: Note: 220 mcg inhaler delivers 200 mcg mometasone furoate per actuation; NAEPP uses doses based on delivery, while manufacturer recommended doses are based on inhaler amount.
Low-dose therapy: 200 mcg/day
Medium-dose therapy: 400 mcg/day
High-dose therapy: >400 mcg/day
Refer to adult dosing.
Asthma: Note: Asmanex Twisthaler (110 mcg and 220 mcg Twisthaler) deliver 100 and 200 mcg mometasone furoate per actuation respectively; NAEPP uses doses based on delivery dose, while manufacturer recommended doses are based on inhaler amount. Maximum effects may not be evident for 1 to 2 weeks or longer; higher doses may provide additional asthma control in patients who do not respond adequately after 2 weeks of therapy. Doses should be titrated to the lowest effective dose once asthma is controlled.
Asmanex Twisthaler (dry powder inhaler):
Children 4 to 11 years (regardless of prior therapy): Note: Use 110 mcg inhaler: Oral inhalation (110 mcg/inhalation): Initial: 110 mcg once daily, administered in the evening. Maximum daily dose: 110 mcg/day
Children ≥12 years and Adolescents: Dosing based on previous asthma therapy.
Patients previously treated with bronchodilators alone or with inhaled corticosteroids: Oral Inhalation (220 mcg/inhalation): Initial: 220 mcg once daily, administered in the evening; may increase dose after 2 weeks if adequate response not obtained. Maximum daily dose: 440 mcg/day; may be administered as 1 inhalation twice daily or 2 inhalations once daily in the evening
Patients previously treated with oral corticosteroids: Oral Inhalation (220 mcg/inhalation): Initial: 440 mcg twice daily. Maximum daily dose: 880 mcg/day
Asmanex HFA: Children ≥12 years and Adolescents: Dosing based on previous asthma therapy.
Patients previously treated with inhaled medium dose corticosteroid: Oral inhalation (100 mcg/inhalation): 200 mcg twice daily; maximum daily dose: 800 mcg/day
Patients previously treated with high-dose inhaled corticosteroids or oral corticosteroids: Oral inhalation (200 mcg/inhalation): 400 mcg twice daily; maximum daily dose: 800 mcg/day
Global Initiative for Asthma Guidelines (GINA 2017): Dry powder inhaler (refers to Asmanex Twisthaler 110 mcg and 220 mcg strengths)
Children 6 to 11 years:
“Low” dose: 110 mcg/day
“Medium” dose: ≥220 to <440 mcg/day
“High” dose: ≥440 mcg/day
Children ≥12 years and Adolescents: Oral inhalation:
“Low” dose: 110 to 220 mcg/day
“Medium” dose: >220 to 440 mcg/day
“High” dose: >440 mcg/day
National Asthma Education and Prevention Program (NAEPP 2007): Dry powder inhaler (refers to Asmanex Twisthaler 220 mcg strength): Children ≥12 years and Adolescents: Oral inhalation:
"Low" dose: 200 mcg/day
"Medium" dose: 400 mcg/day
"High" dose: >400 mcg/day
Conversion from oral systemic corticosteroids to orally inhaled corticosteroids: When using mometasone oral inhalation to help reduce or discontinue oral corticosteroid therapy, begin prednisone taper after at least 1 week of mometasone inhalation therapy; prednisone should be tapered slowly (ie, no faster than 2.5 mg/day on a weekly basis); monitor patients for signs of asthma instability and adrenal insufficiency; decrease mometasone to lowest effective dose after prednisone reduction is complete.
Asmanex HFA: Metered-dose inhaler: Shake well prior to each inhalation. Administer as 2 inhalations twice daily (morning and evening). Prime before first use and when the inhaler has not been used for >5 days by releasing 4 test sprays into the air, away from the face, shaking well before each spray. Rinse mouth with water (without swallowing) after each use. Clean mouthpiece with a dry wipe after every 7 days of use.
Asmanex Twisthaler: Dry-powder inhaler: When administered once daily, administer only in the evening. Exhale fully, then place mouthpiece in mouth holding it in a horizontal position and inhale quickly and deeply. Remove inhaler and hold breath for 10 seconds if possible. Do not breathe out through the inhaler. Rinse mouth after use.
Asmanex Twisthaler may contain lactose.
Asmanex HFA: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not puncture. Do not use or store near heat or open flame; never throw container into fire or incinerator. Exposure to temperatures above 120°F may cause bursting. Discard when dose counter reads “0".
Asmanex Twisthaler: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Discard when dose counter reads "00" or 45 days after opening the foil pouch, whichever comes first.
Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination
Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. Monitor therapy
Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Monitor therapy
Cosyntropin: Corticosteroids (Orally Inhaled) may diminish the diagnostic effect of Cosyntropin. Monitor therapy
CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Orally inhaled fluticasone propionate with a strong CYP3A4 inhibitor is not recommended. Monitor therapy
Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Monitor therapy
Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. Avoid combination
Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification
Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. Monitor therapy
Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine. Avoid combination
Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. Monitor therapy
Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. Monitor therapy
Tobacco (Smoked): May diminish the therapeutic effect of Corticosteroids (Orally Inhaled). Monitor therapy
Central nervous system: Headache (3% to 22%), fatigue (1% to 13%), depression (11%)
Gastrointestinal: Oral candidiasis (≤22%)
Neuromuscular & skeletal: Musculoskeletal pain (8% to 22%), arthralgia (13%)
Respiratory: Sinusitis (3% to 22%), allergic rhinitis (adolescents & adults 14% to 20%; children 4%), upper respiratory tract infection (8% to 15%), pharyngitis (8% to 13%)
1% to 10%:
Central nervous system: Pain (1% to <3%)
Gastrointestinal: Abdominal pain (3% to 6%), dyspepsia (5%), nausea (3%), vomiting (1% to ≤3%), anorexia (1% to <3%), gastroenteritis (1% to <3%)
Genitourinary: Dysmenorrhea (9%), urinary tract infection (children 2%)
Hematologic & oncologic: Bruise (children 2%)
Infection: Influenza (4%), infection (1% to <3%)
Neuromuscular & skeletal: Back pain (6%), myalgia (3%)
Ophthalmic: Increased intraocular pressure (3%)
Otic: Otalgia (1% to <3%)
Respiratory: Sinus congestion (9%), nasopharyngitis (5% to 8%), bronchitis (3%), dry throat (1% to <3%), epistaxis (1% to <3%), flu-like symptoms (1% to <3%), nasal discomfort (1% to <3%), voice disorder (1% to <3%)
Miscellaneous: Fever (children 7%)
Postmarketing and/or case reports: Anaphylaxis, angioedema, blurred vision, bronchospasm, cataract, cough, dyspnea, exacerbation of asthma, glaucoma, growth suppression, hypersensitivity reaction, pruritus, skin rash, wheezing
Concerns related to adverse effects:
• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving ≥20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do not provide the systemic steroid needed to treat patients having trauma, surgery, or infections (particularly gastroenteritis), or other conditions with severe electrolyte loss. Select surgical patients on long-term, high-dose, inhaled corticosteroids should be given stress doses of hydrocortisone intravenously during the surgical period and the dose reduced rapidly within 24 hours after surgery (NAEPP 2007).
• Bronchospasm: Paradoxical bronchospasm that may be life-threatening may occur with use of inhaled bronchodilating agents; reaction should be distinguished from inadequate response. If paradoxical bronchospasm occurs, discontinue mometasone and institute alternative therapy.
• Hypersensitivity: Hypersensitivity reactions (eg, allergic dermatitis, anaphylaxis, angioedema, bronchospasm, flushing, pruritus, rash, urticaria) may occur; discontinue use if reaction occurs.
• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use if possible in patients with ocular herpes; active or quiescent respiratory tuberculosis; or untreated viral, fungal, or bacterial or parasitic systemic infections. Exposure to chickenpox or measles should be avoided; if the patient is exposed, prophylaxis with varicella zoster immune globulin or pooled intravenous immunoglobulin, respectively, may be indicated. If chickenpox develops, treatment with antiviral agents may be considered.
• Oral candidiasis: Local oropharyngeal Candida infections have been reported; if this occurs, treat appropriately while continuing therapy. Patients should be instructed to rinse mouth with water (without swallowing) after each use.
• Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Short-acting beta2-agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Use is contraindicated in status asthmaticus or during other acute asthma episodes requiring intensive measures.
• Bone mineral density: Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants, oral corticosteroids); long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.
• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; blurred vision, increased intraocular pressure, glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in long-term users.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Pediatrics: Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 cm per year [range, 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.
Dosage form specific issues:
• Lactose: Asmanex Twisthaler: May contain lactose; very rare anaphylactic reactions have been reported in patients with milk protein allergy.
• Discontinuation of systemic corticosteroid therapy: A gradual tapering of dose may be required prior to discontinuing therapy; there have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.
• Transfer to oral inhaler: When transferring to oral inhalation therapy from systemic corticosteroid therapy, previously suppressed allergic conditions (rhinitis, conjunctivitis, eczema, arthritis, and eosinophilic conditions) may be unmasked. Withdraw systemic corticosteroid therapy by gradually tapering the dose. Monitor lung function, beta-agonist use, asthma symptoms, and for signs and symptoms of adrenal insufficiency (eg, fatigue, lassitude, weakness, nausea/vomiting, hypotension) during withdrawal.
FEV1, peak flow, and/or other pulmonary function tests; bone mineral density; growth (adolescents and children via stadiometry); signs/symptoms of HPA axis suppression/adrenal insufficiency; possible eosinophilic conditions (including eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]); signs/symptoms of oral candidiasis; asthma symptoms; glaucoma/cataracts
Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications (ACOG 2008; GINA 2018).
Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy (ACOG 2008; GINA 2018; Namazy 2016). Pregnant females adequately controlled on mometasone for asthma may continue therapy; if initiating treatment during pregnancy, use of an agent with more data in pregnant females may be preferred (Namazy 2016).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience headache, rhinitis, nausea, pharyngitis, abdominal pain, muscle pain, or back pain. Have patient report immediately to prescriber signs of infection, signs of adrenal gland problems (severe nausea, vomiting, severe dizziness, passing out, muscle weakness, severe fatigue, mood changes, lack of appetite, or weight loss), severe fatigue, irritability, tremors, tachycardia, confusion, dizziness, sweating, thrush, menstrual pain, severe loss of strength and energy, bone pain, joint pain, flu-like signs, flushing, vision changes, difficulty breathing, wheezing, or cough (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about mometasone
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 19 Reviews
- Drug class: inhaled corticosteroids